Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Two-Way Crossover Study to Determine the Effects of Co-Administration of AZD6140 and Nordette (Combination of Levonorgestrel and Ethinyl Estradiol) After Multiple Oral Doses in Healthy Female Volunteers.

Next Previous
Trial Profile

A Randomised, Double-Blind, Two-Way Crossover Study to Determine the Effects of Co-Administration of AZD6140 and Nordette (Combination of Levonorgestrel and Ethinyl Estradiol) After Multiple Oral Doses in Healthy Female Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Pregnancy; Thromboembolism
  • Focus Pharmacodynamics; Pharmacokinetics

Most Recent Events

  • 21 Jun 2011 Results published in Current Medical Research and Opinion.
  • 03 Dec 2010 Actual end date changed from Nov 2008 to Oct 2008 as reported by ClinicalTrials.gov.
  • 18 Apr 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top